INNOCARE (09969.HK): TYK2 Inhibitor Soficitinib (ICP-332) Meets Primary Endpoint in Phase II for Non-Segmental Vitiligo, 24-Week F-VASI Reduced by Around 39%-41% vs Baseline

NewTimeSpace News: On 16 July 2026, Innocare (09969.HK) issued a voluntary announcement. The Phase II portion of adaptive Phase II/III clinical study evaluating Soficitinib (ICP-332), the Company’s self-discovered next-generation oral TYK2 inhibitor, for adult patients with non-segmental vitiligo successfully achieved its primary endpoint.

For the change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24: the 80mg once-daily arm recorded a 38.8% reduction, the 120mg once-daily arm achieved a 41.2% reduction, while the placebo arm only saw a 2.2% decline. Both treatment arms showed statistically significant differences versus placebo (P<0.0001). Consistent therapeutic benefits were observed across multiple secondary endpoints.

In terms of safety, Soficitinib (ICP-332) was well tolerated, consistent with findings from prior clinical trials, with no new safety signals identified. The study will proceed to the Phase III segment per protocol. The Company plans to communicate with regulatory authorities to further push forward clinical development.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.